Women with obstructive hypertrophic cardiomyopathy (oHCM) often face tougher symptoms and outlook than men. They deal with thicker heart walls, higher pressures, and more daily limits. A new look at the SEQUOIA-HCM trial data checks if the drug aficamten works the same for both sexes. This double-blind study published in the Circulation: Heart Failure analyzed aficamten against placebo in 282 patients. Researchers broke down results by sex to spot any gaps. Women made up 115 of the group. They started older, sicker, and with worse heart function.
Tougher Start for Women at Baseline
Women entered the trial at age 64 on average, versus 56 for men. Their Kansas City Cardiomyopathy Questionnaire scores showed poorer quality of life. NT-proBNP levels ran higher, signaling more heart stress. Peak oxygen uptake (pVO2)—a key fitness measure—was lower. Heart scans revealed smaller left ventricles, higher E/e' ratios (stiffer filling), and steeper LV outflow tract (LVOT) gradients. These gaps highlight why women often fare worse in oHCM. Daily activities like walking or climbing stairs hit harder.
Strong Gains in Exercise Capacity for Both
After 24 weeks, aficamten shone across sexes. Women boosted pVO2 by 1.5 ml/kg/min (95% CI +0.7 to +2.4), men by 2.0 (+0.9 to +3.0). Both hit the main goal: better peak exercise ability. Stats adjusted for baseline, beta-blockers, and test type. No big sex difference emerged. Placebo groups saw little change. This means aficamten eases the heart's squeeze, letting patients push harder without blackout risks from blockages.
Symptom Relief and Echo Wins
Quality of life jumped too. Women's KCCQ scores rose 11 points (6-15), men's by 6 (2-9)—edging toward better for women (p=0.08). LVOT gradients dropped sharply at rest and with Valsalva strain in both—no sex gap (p≥0.13). Women scored extra on diastolic function: lateral E/e' fell more (p=0.01). NT-proBNP dropped similarly—about half in both groups (p=0.10). Fewer symptoms, better heart relaxation, lower stress markers. Patients reported easier breathing and energy.
Why This Changes HCM Care
oHCM hits women late and hard, often delaying diagnosis. Aficamten, a cardiac myosin inhibitor, relaxes thick muscle without full beta-blocker side effects. SEQUOIA-HCM proves it closes the sex gap. Women, despite starting behind, gained as much or more on symptoms and echoes. This backs its use in real clinics. Think of a oHCM patient: a 65-year-old woman gasping on mild exertion, high gradient on echo. Aficamten could transform her life.
Trials like this guide FDA nods and guidelines. Safety held up with no major sex issues. Future steps include long-term data, diverse groups beyond trials.